MCID: THR014
MIFTS: 65

Thrombocytopenia

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thrombocytopenia

Summaries for Thrombocytopenia

PubMed Health : 64 About thrombocytopenia: Thrombocytopenia (THROM-bo-si-to-PE-ne-ah) is a condition in which your blood has a lower than normal number of blood cell fragments called platelets (PLATE-lets).Platelets are made in your bone marrow along with other kinds of blood cells. They travel through your blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets also are called thrombocytes (THROM-bo-sites) because a clot also is called a thrombus.

MalaCards based summary : Thrombocytopenia is related to thrombocytopenia 1 and thrombocytopenia-absent radius syndrome. An important gene associated with Thrombocytopenia is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Tight junction and Response to elevated platelet cytosolic Ca2+. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and t cells, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A blood platelet disease characterized by low a platelet count in the blood.

Wikipedia : 77 Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as... more...

Related Diseases for Thrombocytopenia

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia Ankrd26-Related Thrombocytopenia
Myh9 Related Thrombocytopenia

Diseases related to Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 873)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia 1 34.5 GATA1 HOXA11 WAS
2 thrombocytopenia-absent radius syndrome 34.1 ANKRD26 GATA1 GP1BA MPL RBM8A
3 thrombocytopenia 2 34.1 ANKRD26 MASTL
4 autosomal thrombocytopenia with normal platelets 33.7 CYCS MASTL
5 thrombocytopenia due to platelet alloimmunization 33.2 GP9 ITGA2 ITGA2B ITGB3 MPL MYH9
6 fetal and neonatal alloimmune thrombocytopenia 33.0 GP1BA GP1BB ITGA2 ITGA2B ITGB3
7 thrombocytopenic purpura, autoimmune 33.0 GP1BA IL11 ITGA2B ITGB3 MPL
8 platelet disorder, familial, with associated myeloid malignancy 32.7 ANKRD26 ETV6
9 primary thrombocytopenia 32.6 ADAMTS13 GP1BA ITGA2 ITGA2B ITGB3 MPL
10 myh-9 related disease 32.2 ANKRD26 GP1BA MYH9
11 gray platelet syndrome 32.2 GATA1 GP9 MASTL
12 aplastic anemia 31.8 GATA1 IL11 ITGA2B MPL
13 bernard-soulier syndrome 31.1 GP1BA GP1BB GP9 ITGA2 ITGA2B ITGB3
14 bleeding disorder, platelet-type, 16 30.2 ITGA2B ITGB3
15 purpura 30.1 ADAMTS13 GP1BB ITGA2B ITGB3 MPL
16 blood platelet disease 29.8 ADAMTS13 GP1BA GP1BB GP9 ITGA2B ITGB3
17 essential thrombocythemia 29.7 GATA1 GP1BA IL11 ITGA2B ITGB3 MPL
18 myocardial infarction 29.4 ADAMTS13 GP1BA ITGA2 ITGA2B ITGB3
19 autosomal dominant macrothrombocytopenia 29.4 GP1BA GP1BB ITGA2B ITGB3 MYH9
20 thrombasthenia 29.4 GP1BA GP9 ITGA2 ITGA2B ITGB3
21 megakaryocytic leukemia 29.4 GATA1 IL11 ITGA2B
22 hemorrhagic cystitis 29.3 CYCS IL11
23 glanzmann thrombasthenia 29.2 GP1BA GP9 ITGA2 ITGA2B ITGB3
24 heparin-induced thrombocytopenia 12.6
25 amegakaryocytic thrombocytopenia, congenital 12.6
26 thrombocytopenia, paris-trousseau type 12.5
27 radioulnar synostosis with amegakaryocytic thrombocytopenia 1 12.5
28 thrombocytopenia with beta-thalassemia, x-linked 12.5
29 dyserythropoietic anemia and thrombocytopenia 12.5
30 thrombocytopenia 4 12.4
31 hemangioma-thrombocytopenia syndrome 12.4
32 thrombocytopenia, x-linked, with or without dyserythropoietic anemia 12.4
33 thrombocytopenia 5 12.4
34 acquired amegakaryocytic thrombocytopenia 12.3
35 thrombocytopenia 3 12.3
36 thrombocytopenia 6 12.3
37 radioulnar synostosis with amegakaryocytic thrombocytopenia 2 12.3
38 acquired thrombocytopenia 12.3
39 myh9 related thrombocytopenia 12.3
40 thrombocytopenia, anemia, and myelofibrosis 12.2
41 thrombocytopenia, cyclic 12.2
42 multifocal lymphangioendotheliomatosis with thrombocytopenia 12.1
43 transient neonatal thrombocytopenia 12.1
44 thrombocytopenia robin sequence 12.1
45 ankrd26-related thrombocytopenia 12.1
46 hereditary thrombocytopenia with normal platelets 12.0
47 wiskott-aldrich syndrome 12.0
48 thrombocytopenia with elevated serum iga and renal disease 12.0
49 osteochondrodysplasia, rhizomelic, with callosal agenesis, thrombocytopenia, hydrocephalus, and hypertension 11.9
50 skeleto cardiac syndrome with thrombocytopenia 11.9

Graphical network of the top 20 diseases related to Thrombocytopenia:



Diseases related to Thrombocytopenia

Symptoms & Phenotypes for Thrombocytopenia

MGI Mouse Phenotypes related to Thrombocytopenia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 CYCS ETV6 GATA1 GP1BA HOXA11 ITGA2
2 hematopoietic system MP:0005397 9.97 ADAMTS13 CYCS ETV6 GATA1 GP1BA GP1BB
3 embryo MP:0005380 9.86 CYCS ETV6 GATA1 ITGA2B ITGB3 MASTL
4 homeostasis/metabolism MP:0005376 9.73 ADAMTS13 ANKRD26 ETV6 GATA1 GP1BA GP1BB
5 immune system MP:0005387 9.28 ADAMTS13 CYCS ETV6 GATA1 ITGA2B ITGB3

Drugs & Therapeutics for Thrombocytopenia

PubMedHealth treatment related to Thrombocytopenia: 64

Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding.If your condition is mild, you may not need treatment. A fully normal platelet count isn't necessary to prevent bleeding, even with severe cuts or accidents.Thrombocytopenia often improves when its underlying cause is treated. People who inherit the condition usually don't need treatment.If a reaction to a medicine is causing a low platelet count, your doctor may prescribe another medicine. Most people recover after the initial medicine has been stopped. For heparin-induced thrombocytopenia (HIT), stopping the heparin isn't enough. Often, you'll need another medicine to prevent blood clotting.If your immune system is causing a low platelet count, your doctor may prescribe medicines to suppress the immune system.

Drugs for Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 770)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
3 Certoparin Approved, Investigational Phase 4,Phase 3
4
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
5
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
6
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
7
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
8
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 128270-60-0 16129704
9
Clopidogrel Approved Phase 4,Phase 3,Phase 2 120202-66-6, 113665-84-2 60606
10
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
11
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 616-91-1 12035
12
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
13
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
14
Hydroxychloroquine Approved Phase 4,Phase 3 118-42-3 3652
15
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 446-86-6 2265
16
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
17
Oprelvekin Approved, Investigational Phase 4,Phase 2,Phase 3 145941-26-0
18
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
19
Enoxaparin Approved Phase 4,Phase 2,Phase 3 9005-49-6 772
20
Fluorouracil Approved Phase 4,Phase 3,Phase 1,Phase 2 51-21-8 3385
21
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 6857599 5310940 9887054 43805
22
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
23
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
24
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
25
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
28
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
30
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 175865-60-8 64147
31
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
32
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613
33
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
34
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
35
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3 7487-88-9 24083
36
Linezolid Approved, Investigational Phase 4,Phase 1,Phase 2 165800-03-3 441401
37
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
38
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
39
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 1 99-66-1 3121
40
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
41
Fondaparinux Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104993-28-4
42
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 216503-57-0
43
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
44
carbamide peroxide Approved Phase 4,Not Applicable 124-43-6
45
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
46
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 21704 32326
47
Fludarabine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
48
Argatroban Approved, Investigational Phase 4,Phase 3,Phase 2 74863-84-6 152951
49
Abciximab Approved Phase 4,Phase 3 143653-53-6
50
Nadroparin Approved, Investigational Phase 4

Interventional clinical trials:

(show top 50) (show all 1673)
# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 The HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
3 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Unknown status NCT02355873 Phase 4
4 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
5 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
6 Withholding Feeds During Red Blood Cell Transfusion and TRAGI Unknown status NCT02132819 Phase 4
7 Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI Unknown status NCT00476944 Phase 4
8 Impact of Heparin on the Need for Mechanical Ventilation in Neonates Unknown status NCT00196469 Phase 4 heparin
9 Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
10 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4 N-acetylcysteine
11 Low Dose Calcium to Prevent Preeclampsia Unknown status NCT02338687 Phase 4
12 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
13 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Completed NCT02267993 Phase 4 recombinant human thrombopoietin
14 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
15 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
16 Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL Completed NCT02314273 Phase 4 rhIL-11
17 Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients Completed NCT00759083 Phase 4 bivalirudin
18 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
19 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
20 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
21 Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion Completed NCT01955811 Phase 4 Administration of platelet concentrate and taking blood samples
22 Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process Completed NCT01789762 Phase 4
23 EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study Completed NCT00169819 Phase 4 Abciximab
24 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
25 Enoxaparin Versus Unfractionated Heparin in PCI Completed NCT00439855 Phase 4 Enoxaparin i.v.;unfractionated heparin
26 Nadroparin for the Initial Treatment of Pulmonary Thromboembolism Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
27 Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3) Completed NCT00133250 Phase 4 Abciximab
28 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
29 Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin Completed NCT00622648 Phase 4 Enoxaparin;Placebo
30 EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization Completed NCT00077753 Phase 4 enoxaparin sodium
31 Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients Completed NCT03114995 Phase 4 Tirofiban
32 Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation Completed NCT00943228 Phase 4 mycophenolate mofetil
33 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
34 Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis Completed NCT02215993 Phase 4 Prasugrel;Ticagrelor
35 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
36 Antiplatelet Therapy After Cardiac Arrest Completed NCT02224274 Phase 4 Clopidogrel;Ticagrelor
37 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
38 Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time Completed NCT00929279 Phase 4 bolus+infusion;abciximab bolus only regimen
39 Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement Completed NCT00362492 Phase 4
40 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
41 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis Completed NCT00913133 Phase 4 Desirudin
42 VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel Completed NCT01684813 Phase 4 Prasugrel.;Clopidogrel
43 Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients Completed NCT00895583 Phase 4 Tacrolimus;Sirolimus;Tacrolimus
44 A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) Completed NCT01585324 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin [Copegus]
45 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
46 BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial. Completed NCT01696110 Phase 4 Bivalirudin;heparin;heparin plus tirofiban
47 How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention Completed NCT01519518 Phase 4 unfractionated heparin;Bivalirudin
48 Once-a-day Immunosuppression(CISECON_a_day) Completed NCT01964014 Phase 4 advagrf
49 DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) Completed NCT01743521 Phase 4 TPV/PEG-IFN/RBV
50 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib

Search NIH Clinical Center for Thrombocytopenia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Thrombocytopenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: thrombocytopenia

Genetic Tests for Thrombocytopenia

Genetic tests related to Thrombocytopenia:

# Genetic test Affiliating Genes
1 Thrombocytopenia 30

Anatomical Context for Thrombocytopenia

MalaCards organs/tissues related to Thrombocytopenia:

42
Myeloid, Bone, T Cells, Testes, Bone Marrow, Kidney, B Cells

Publications for Thrombocytopenia

Articles related to Thrombocytopenia:

(show top 50) (show all 7456)
# Title Authors Year
1
Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. ( 30747734 )
2019
2
Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. ( 29747993 )
2019
3
The world's first clinical trial for an aplastic anemia patient with thrombocytopenia administering platelets generated from autologous iPS cells. ( 30535854 )
2019
4
Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia. ( 30602063 )
2019
5
A rare case of immune thrombocytopenia secondary to breast cancer. ( 30656035 )
2019
6
First case of neutropenia and thrombocytopenia in the setting of cerebral cavernous malformation 3. ( 30904992 )
2019
7
Suspected Compartment Syndrome, Consumptive Thrombocytopenia, and Anemia Secondary to a Ruptured Arterial Aneurysm or Pseudoaneurysm Following Multiple Stifle Surgeries. ( 30653363 )
2019
8
Recurrent Severe Iron Deficiency Anemia and Thrombocytopenia in an Adolescent Male. ( 29668536 )
2019
9
Early diagnosis of necrotizing enterocolitis by plasma RELMβ and thrombocytopenia in preterm infants: A pilot study. ( 30799148 )
2019
10
Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. ( 30478722 )
2019
11
Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. ( 30828796 )
2019
12
The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper. ( 30609018 )
2019
13
Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. ( 30664724 )
2019
14
Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia. ( 30582672 )
2019
15
Limited impact of clinician education on reducing inappropriate PF4 testing for heparin-induced thrombocytopenia. ( 30612329 )
2019
16
An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. ( 30640980 )
2019
17
Fondaparinux in heparin-induced thrombocytopenia: A decade's worth of clinical experience. ( 30656269 )
2019
18
Successful Use of Cangrelor and Heparin for Cardiopulmonary Bypass in a Patient With Heparin-Induced Thrombocytopenia and End-Stage Renal Disease: A Case Report. ( 30688681 )
2019
19
A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia. ( 30693813 )
2019
20
False-Negative Platelet Factor 4 Antibodies and Serotonin Release Assay and the Utility of Repeat Testing in the Diagnosis of Heparin-Induced Thrombocytopenia and Thrombosis. ( 30729049 )
2019
21
Heparin-Induced Thrombocytopenia: Finding the Needle in the Haystack. ( 30768506 )
2019
22
High-dose Intravenous Immunoglobulin to Treat Spontaneous Heparin-induced Thrombocytopenia Syndrome. ( 30773806 )
2019
23
Development of an algorithm for the systematic evaluation of patients with suspected heparin-induced thrombocytopenia. ( 30790161 )
2019
24
Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia. ( 30828164 )
2019
25
Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay. ( 30850576 )
2019
26
Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes. ( 30854309 )
2019
27
Routine monitoring for heparin-induced thrombocytopenia following lower limb arthroplasty: Is it necessary? A prospective study in a UK district general hospital. ( 30878232 )
2019
28
Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. ( 30899022 )
2019
29
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. ( 30903805 )
2019
30
Mesenteric Ischemia Caused by Heparin-induced Thrombocytopenia: A Case Report. ( 30911456 )
2019
31
Heparin-Induced Thrombocytopenia in Infants after Heart Surgery. ( 29605959 )
2019
32
Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia. ( 30804674 )
2019
33
Thrombocytopenia and Predisposition to Acute Myeloid Leukemia due to Mosaic Ring 21 with Loss of RUNX1: Cytogenetic and Molecular Characterization. ( 30800047 )
2019
34
Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia. ( 30792200 )
2019
35
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). ( 30762895 )
2019
36
Hemoperitoneum after Ovulation in Systemic Lupus Erythematosus and Autoimmune Thrombocytopenia. ( 30792931 )
2019
37
Thrombocytopenia Impairs Host Defense Against Burkholderia pseudomallei (Melioidosis). ( 30312422 )
2019
38
Lethal thrombocytopenia in a patient treated with avelumab for metastatic Merkel cell carcinoma. ( 30549433 )
2019
39
Fulminant myocarditis associated with severe fever with thrombocytopenia syndrome: a case report. ( 30885147 )
2019
40
Circulating antiplatelet antibodies in pregnant women with immune thrombocytopenic purpura as predictors of thrombocytopenia in the newborns. ( 30614745 )
2019
41
Mean Platelet Volume, Platelet Distribution Width, and Platelet Count, in Connection with Immune Thrombocytopenic Purpura and Essential Thrombocytopenia. ( 30726936 )
2019
42
A Novel Association between Antiretroviral Therapy and Drug-Induced Immune Thrombocytopenia Purpura. ( 30840965 )
2019
43
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. ( 30880797 )
2019
44
Primary cardiac synovial sarcoma that was continuous with the mitral valve caused severe thrombocytopenia: a case report. ( 30717777 )
2019
45
Severe fever with thrombocytopenia syndrome: comparison with scrub typhus and clinical diagnostic prediction. ( 30782137 )
2019
46
Unusual presentations of sitosterolemia limited to hematological abnormalities: A report of 4 cases presenting with stomatocytic anemia and thrombocytopenia with macrothrombocytes. ( 30697800 )
2019
47
TAFRO Syndrome with an Anterior Mediastinal Mass and Lethal Autoantibody-Mediated Thrombocytopenia: An Autopsy Case Report. ( 30799408 )
2019
48
Quantitative proteomic analysis reveals unfolded protein response involved in severe fever with thrombocytopenia syndrome virus infection. ( 30842332 )
2019
49
Systematic review and meta-analysis of thrombocytopenia as a predictor of post-hepatectomy liver failure. ( 30846279 )
2019
50
Decitabine improves platelet recovery by down-regulating IL-8 level in MDS/AML patients with thrombocytopenia. ( 30846359 )
2019

Variations for Thrombocytopenia

ClinVar genetic disease variations for Thrombocytopenia:

6 (show top 50) (show all 438)
# Gene Variation Type Significance SNP ID Assembly Location
1 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh38 Chromosome 12, 11869601: 11869601
2 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh37 Chromosome 12, 12022535: 12022535
3 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh38 Chromosome 12, 11884541: 11884541
4 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh37 Chromosome 12, 12037475: 12037475
5 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh37 Chromosome 12, 12038902: 12038902
6 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh38 Chromosome 12, 11885968: 11885968
7 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh37 Chromosome 12, 12038855: 12038859
8 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh38 Chromosome 12, 11885921: 11885925
9 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh37 Chromosome 12, 12037415: 12037415
10 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh38 Chromosome 12, 11884481: 11884481
11 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh37 Chromosome 22, 29091857: 29091857
12 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh38 Chromosome 22, 28695869: 28695869
13 COL4A4 NM_000092.4(COL4A4): c.4217-15T> C single nucleotide variant Conflicting interpretations of pathogenicity rs200926310 GRCh37 Chromosome 2, 227877028: 227877028
14 COL4A4 NM_000092.4(COL4A4): c.4217-15T> C single nucleotide variant Conflicting interpretations of pathogenicity rs200926310 GRCh38 Chromosome 2, 227012312: 227012312
15 CYCS NM_018947.5(CYCS): c.-6T> G single nucleotide variant Benign/Likely benign rs11267038 GRCh37 Chromosome 7, 25163744: 25163744
16 CYCS NM_018947.5(CYCS): c.-6T> G single nucleotide variant Benign/Likely benign rs11267038 GRCh38 Chromosome 7, 25124125: 25124125
17 ANKRD26 NM_014915.2(ANKRD26): c.4542T> A (p.Phe1514Leu) single nucleotide variant Benign/Likely benign rs2274741 GRCh37 Chromosome 10, 27303605: 27303605
18 ANKRD26 NM_014915.2(ANKRD26): c.4542T> A (p.Phe1514Leu) single nucleotide variant Benign/Likely benign rs2274741 GRCh38 Chromosome 10, 27014676: 27014676
19 ANKRD26 NM_014915.2(ANKRD26): c.4145T> A (p.Phe1382Tyr) single nucleotide variant Benign/Likely benign rs78251061 GRCh38 Chromosome 10, 27022628: 27022628
20 ANKRD26 NM_014915.2(ANKRD26): c.4145T> A (p.Phe1382Tyr) single nucleotide variant Benign/Likely benign rs78251061 GRCh37 Chromosome 10, 27311557: 27311557
21 ANKRD26 NM_014915.2(ANKRD26): c.3972+3A> G single nucleotide variant Benign/Likely benign rs72807627 GRCh38 Chromosome 10, 27028849: 27028849
22 ANKRD26 NM_014915.2(ANKRD26): c.3972+3A> G single nucleotide variant Benign/Likely benign rs72807627 GRCh37 Chromosome 10, 27317778: 27317778
23 ANKRD26 NM_014915.2(ANKRD26): c.3913G> A (p.Val1305Ile) single nucleotide variant Benign/Likely benign rs10829163 GRCh38 Chromosome 10, 27028911: 27028911
24 ANKRD26 NM_014915.2(ANKRD26): c.3913G> A (p.Val1305Ile) single nucleotide variant Benign/Likely benign rs10829163 GRCh37 Chromosome 10, 27317840: 27317840
25 ANKRD26 NM_014915.2(ANKRD26): c.3658G> C (p.Val1220Leu) single nucleotide variant Benign/Likely benign rs12572862 GRCh38 Chromosome 10, 27033374: 27033374
26 ANKRD26 NM_014915.2(ANKRD26): c.3658G> C (p.Val1220Leu) single nucleotide variant Benign/Likely benign rs12572862 GRCh37 Chromosome 10, 27322303: 27322303
27 ANKRD26 NM_014915.2(ANKRD26): c.3384G> A (p.Lys1128=) single nucleotide variant Benign/Likely benign rs41299210 GRCh37 Chromosome 10, 27323995: 27323995
28 ANKRD26 NM_014915.2(ANKRD26): c.3384G> A (p.Lys1128=) single nucleotide variant Benign/Likely benign rs41299210 GRCh38 Chromosome 10, 27035066: 27035066
29 ANKRD26 NM_014915.2(ANKRD26): c.2978A> C (p.Glu993Ala) single nucleotide variant Benign/Likely benign rs61745662 GRCh37 Chromosome 10, 27324401: 27324401
30 ANKRD26 NM_014915.2(ANKRD26): c.2978A> C (p.Glu993Ala) single nucleotide variant Benign/Likely benign rs61745662 GRCh38 Chromosome 10, 27035472: 27035472
31 ANKRD26 NM_014915.2(ANKRD26): c.2376-4G> A single nucleotide variant Benign/Likely benign rs75445709 GRCh37 Chromosome 10, 27326987: 27326987
32 ANKRD26 NM_014915.2(ANKRD26): c.2376-4G> A single nucleotide variant Benign/Likely benign rs75445709 GRCh38 Chromosome 10, 27038058: 27038058
33 ANKRD26 NM_014915.2(ANKRD26): c.1596_1598delAGA (p.Glu533del) deletion Benign/Likely benign rs138423863 GRCh37 Chromosome 10, 27342286: 27342288
34 ANKRD26 NM_014915.2(ANKRD26): c.1596_1598delAGA (p.Glu533del) deletion Benign/Likely benign rs138423863 GRCh38 Chromosome 10, 27053357: 27053359
35 ANKRD26 NM_014915.2(ANKRD26): c.1564+6T> C single nucleotide variant Benign/Likely benign rs149655759 GRCh38 Chromosome 10, 27060339: 27060339
36 ANKRD26 NM_014915.2(ANKRD26): c.1564+6T> C single nucleotide variant Benign/Likely benign rs149655759 GRCh37 Chromosome 10, 27349268: 27349268
37 ANKRD26 NM_014915.2(ANKRD26): c.1273A> G (p.Ile425Val) single nucleotide variant Benign/Likely benign rs12359281 GRCh37 Chromosome 10, 27353007: 27353007
38 ANKRD26 NM_014915.2(ANKRD26): c.1273A> G (p.Ile425Val) single nucleotide variant Benign/Likely benign rs12359281 GRCh38 Chromosome 10, 27064078: 27064078
39 ANKRD26 NM_014915.2(ANKRD26): c.1207+15A> G single nucleotide variant Benign/Likely benign rs115864032 GRCh37 Chromosome 10, 27356071: 27356071
40 ANKRD26 NM_014915.2(ANKRD26): c.1207+15A> G single nucleotide variant Benign/Likely benign rs115864032 GRCh38 Chromosome 10, 27067142: 27067142
41 ANKRD26 NM_014915.2(ANKRD26): c.624A> G (p.Val208=) single nucleotide variant Benign/Likely benign rs2297145 GRCh37 Chromosome 10, 27381349: 27381349
42 ANKRD26 NM_014915.2(ANKRD26): c.624A> G (p.Val208=) single nucleotide variant Benign/Likely benign rs2297145 GRCh38 Chromosome 10, 27092420: 27092420
43 ANKRD26 NM_014915.2(ANKRD26): c.59A> G (p.Gln20Arg) single nucleotide variant Benign/Likely benign rs7897309 GRCh37 Chromosome 10, 27389197: 27389197
44 ANKRD26 NM_014915.2(ANKRD26): c.59A> G (p.Gln20Arg) single nucleotide variant Benign/Likely benign rs7897309 GRCh38 Chromosome 10, 27100268: 27100268
45 ANKRD26 NM_014915.2(ANKRD26): c.-59G> A single nucleotide variant Benign/Likely benign rs3737056 GRCh37 Chromosome 10, 27389314: 27389314
46 ANKRD26 NM_014915.2(ANKRD26): c.-59G> A single nucleotide variant Benign/Likely benign rs3737056 GRCh38 Chromosome 10, 27100385: 27100385
47 ANKRD26 NM_014915.2(ANKRD26): c.-140C> G single nucleotide variant Benign/Likely benign rs41299222 GRCh38 Chromosome 10, 27100466: 27100466
48 ANKRD26 NM_014915.2(ANKRD26): c.-140C> G single nucleotide variant Benign/Likely benign rs41299222 GRCh37 Chromosome 10, 27389395: 27389395
49 MASTL NM_032844.4(MASTL): c.-27T> C single nucleotide variant Benign/Likely benign rs7907981 GRCh37 Chromosome 10, 27444329: 27444329
50 MASTL NM_032844.4(MASTL): c.-27T> C single nucleotide variant Benign/Likely benign rs7907981 GRCh38 Chromosome 10, 27155400: 27155400

Expression for Thrombocytopenia

Search GEO for disease gene expression data for Thrombocytopenia.

Pathways for Thrombocytopenia

Pathways related to Thrombocytopenia according to KEGG:

38
# Name Kegg Source Accession
1 Tight junction hsa04530

Pathways related to Thrombocytopenia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.16 GATA1 GP1BA GP1BB GP9 ITGA2 ITGA2B
2
Show member pathways
12.76 ITGA2 ITGA2B ITGB3 MYH9 WAS
3 12.47 ITGA2 ITGA2B ITGB3 MYH9 WAS
4
Show member pathways
12.08 CYCS ITGA2 ITGA2B ITGB3 MYH9 WAS
5
Show member pathways
12.06 GP1BA GP1BB GP9 ITGA2 ITGA2B ITGB3
6 11.89 GP1BA GP1BB GP9 ITGA2 ITGA2B ITGB3
7
Show member pathways
11.86 ITGA2 ITGA2B ITGB3
8 11.71 CYCS ITGA2 ITGA2B
9 11.7 GP1BA IL11 ITGA2 ITGA2B ITGB3 MPL
10 11.65 ITGA2 ITGA2B ITGB3
11 11.47 GP1BB GP9 ITGA2 ITGA2B ITGB3
12 11.46 ITGA2 ITGA2B ITGB3
13 11.42 GATA1 GP9 ITGA2B ITGB3
14
Show member pathways
11.42 GP1BA GP1BB GP9 ITGA2B ITGB3 MPL
15 11.38 ITGA2 ITGA2B ITGB3 MYH9
16 11.24 IL11 ITGA2 ITGA2B ITGB3
17 11.15 GP1BA GP1BB GP9 IL11 ITGA2 ITGA2B
18 10.91 ITGA2B ITGB3
19 10.67 GP1BA GP1BB GP9 ITGA2
20 10.63 GP1BA GP1BB GP9

GO Terms for Thrombocytopenia

Cellular components related to Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 ADAMTS13 GP1BA ITGA2 ITGA2B ITGB3 MPL
2 platelet alpha granule membrane GO:0031092 9.16 ITGA2B ITGB3
3 integrin complex GO:0008305 8.8 ITGA2 ITGA2B ITGB3

Biological processes related to Thrombocytopenia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.91 GP1BA GP1BB GP9 ITGA2 ITGA2B ITGB3
2 cell-matrix adhesion GO:0007160 9.73 ADAMTS13 ITGA2 ITGA2B ITGB3
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 GATA1 IL11 ITGB3
4 regulation of megakaryocyte differentiation GO:0045652 9.65 GATA1 GP1BA ITGA2B
5 platelet activation GO:0030168 9.65 ADAMTS13 GP1BA GP1BB GP9 ITGB3
6 hemostasis GO:0007599 9.62 ADAMTS13 GP1BA GP1BB GP9
7 cell adhesion mediated by integrin GO:0033627 9.58 ITGA2 ITGB3
8 blood coagulation, intrinsic pathway GO:0007597 9.58 GP1BA GP1BB GP9
9 actin filament-based movement GO:0030048 9.57 MYH9 WAS
10 platelet formation GO:0030220 9.56 GATA1 MYH9
11 blood coagulation GO:0007596 9.56 ADAMTS13 GATA1 GP1BA GP1BB GP9 ITGA2
12 cell-substrate adhesion GO:0031589 9.55 ITGA2 ITGB3
13 integrin-mediated signaling pathway GO:0007229 9.55 ADAMTS13 ITGA2 ITGA2B ITGB3 MYH9
14 mesodermal cell differentiation GO:0048333 9.54 ITGA2 ITGB3
15 positive regulation of leukocyte migration GO:0002687 9.52 ITGA2 ITGA2B
16 response to amine GO:0014075 9.49 ADAMTS13 ITGA2
17 megakaryocyte differentiation GO:0030219 9.46 GATA1 IL11
18 platelet aggregation GO:0070527 9.1 GATA1 GP1BA ITGA2B ITGB3 MPL MYH9

Molecular functions related to Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinogen binding GO:0070051 8.96 ITGA2B ITGB3
2 integrin binding GO:0005178 8.92 ADAMTS13 ITGA2 ITGB3 MYH9
3 protein binding GO:0005515 10.06 ADAMTS13 ANKRD26 CYCS ETV6 GATA1 GP1BA

Sources for Thrombocytopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....